CFIA cancels the Safe Food for Canadians licence #9K9WDGDF of Usine Amsellem inc.

Jan 07, 2020

OTTAWA – After a thorough and comprehensive review, the Canadian Food Inspection Agency (CFIA) has cancelled the Safe Food for Canadians licence #9K9WDGDF of Usine Amsellem inc, effective January 6, 2020.

The decision was made after the Agency identified during a food safety investigation that it had received false or misleading information and false or misleading statements from the licence holder relating to one test result for Salmonella bacteria.

Effective immediately, Usine Amsellem inc. is no longer able to conduct any activity that is identified in their licence such as preparing food for export or to be sent or conveyed from one province or territory to another.

A recall of dry beef sausage produced by this licence holder was published on December 4, 2019, due to possible Salmonella contamination. Although no cases of illness associated with the consumption of this product have been reported, the CFIA took the necessary measures to protect consumers as soon as it was determined that a product was potentially contaminated.

CFIA has now concluded the food safety investigation and no additional recalls are expected in respect of this investigation.

Source : Government of Canada

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.